Loading stock data…
AtriCure, Inc. (ATRC)
$28.70-1.48 (-4.90%)
Market ClosedLast close Jun 29
AtriCure, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AtriCure, Inc. in the Healthcare sector is trading at $28.70 with a market capitalization of $1.5B. Wall Street consensus targets $47.00 (8 analysts), implying a +63.8% move over the next 12 months. The stock is currently near its 52-week low of $25.36, remaining 13.6% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +63.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $141.25M↑ | $140.50M↑ | $134.27M↓ | $136.14M↑ | $123.62M |
| Gross Profit | $109.31M↑ | $105.34M↑ | $101.33M↓ | $101.48M↑ | $92.63M |
| Operating Income | $526,000↓ | $2.49M↑ | $208,000↑ | -$6.19M↓ | -$5.95M |
| Net Income | $108,000↓ | $1.76M↑ | -$267,000↑ | -$6.19M↑ | -$6.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.93%
Volume
Today's trading volume
1.90M
Recent News
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Acceleration Draws Investor Attention
AtriCure (ATRC) has accelerated its BoxX-NoAF clinical trial by 12 months, with patient enrollment now targeted for completion by year end. This development is drawing fresh attention from investors assessing the stock’s risk reward profile. See our latest analysis for AtriCure. The accelerated BoxX-NoAF trial sits against a mixed share price backdrop, with AtriCure’s stock at US$27.10 after a modest 3.12% 1 month share price gain, but a much steeper year to date share price decline of 30.99%...
AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule
AtriCure, Inc. (NASDAQ:ATRC) is one of the top small cap stocks with huge growth potential. On May 6, Needham reiterated its Buy rating and $45 price target on AtriCure, Inc. (NASDAQ:ATRC) after the company delivered blowout Q1 2026 earnings. AtriCure shared the earnings on May 5 and reported quarterly worldwide revenue of $141.2 million, a […]